The effect of sevelamer on serum calcification propensity in patients with chronic kidney disease: the results of a multicentre, double-blind, placebo-controlled, randomized clinical trial
A 12-week course of the non-calcium-containing phosphate binder sevelamer carbonate was not associated with a significant change in T50 in patients with stage 3b/4 CKD. Phosphate binders might not be an effective strategy for modifying serum calcification propensity in non-dialysis-dependent patients with CKD.
Authors
- Pablo Ureña‐Torres (ORCID: https://orcid.org/0000-0001-6757-1906)
- François Brazier (ORCID: https://orcid.org/0000-0002-3898-4389)
- Solène M. Laville (ORCID: https://orcid.org/0000-0002-0214-5567)
- Sophie Liabeuf (ORCID: https://orcid.org/0000-0001-5384-9006)
- Gabriel Choukroun (ORCID: https://orcid.org/0000-0003-0772-5656)
- Maxime Pluquet (ORCID: https://orcid.org/0000-0003-4330-2925)
- N. El Esper
- Saïd Kamel (ORCID: https://orcid.org/0009-0008-4801-4846)
Institutions
- Université Paris Cité (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Association pour l'Utilisation du Rein Artificiel (FR)
- Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires (FR)
- Université de Picardie Jules Verne (FR)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1093/ckj/sfae343
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Sanofi Genzyme